London · Delayed Price · Currency is GBP · Price in GBX Animalcare Group Earnings Call Transcripts
Fiscal Year 2026
-
Ambitious plans target GBP 150 million revenue by 2030, driven by organic growth, innovation, and M&A, with a focus on commercial excellence, manufacturing consolidation, and a robust R&D pipeline. Equine and dental franchises, along with global expansion and disciplined capital allocation, underpin the strategy.
Fiscal Year 2025
-
Revenue grew 18.3% year-over-year, driven by Randlab's strong integration and organic performance. Margins and cash flow improved, with robust investment in R&D and a healthy M&A pipeline. Regulatory and FX headwinds were managed, and the outlook remains positive.
Fiscal Year 2024
-
Strong H1 organic growth was driven by flagship products and robust performance in production and equine segments. Significant cash from disposals is fueling an active M&A pipeline, with a focus on expanding geographic reach and product innovation. Confident outlook for H2, with continued investment in operational excellence and new product launches.
-
Delivered 5% organic revenue growth and improved gross margins in H1 2024, driven by strong performances from Daxocox and Plaqtiv+, and a robust production animal segment. Balance sheet strengthened by disposals, supporting active M&A and new product launches planned for 2025.